Malaria Minute

The prevalence of insecticide resistance increases in Africa and researchers find that the malaria parasite interferes with red blood cell development to ensure gametocyte maturation.

CDK5 regulates atypical cell division in gametogony and is essential for DNA replication, and researchers assess whether two experimental vaccines can be combined to create a multistage vaccine against malaria.

Researchers evaluate the immunogenicity of the AGS-v vaccine which targets saliva produced by Anopheles gambiae mosquitoes.

New mutations to the quinoline drug family identified in South America and Asia are not prevalent in Africa and scientists evaluate a new field-based malaria blood test.

Artefenomel is assessed against Plasmodium vivax infection in humans to determine the minimum effective dose required for parasite clearance and LSHTM launch a beta version of The Global Vector Hub.

The spleen plays a major role in the expression of P. vivax genes and the production of antigens associated with clinical protection, and scientists develop an AI that can detect Plasmodium infection in the blood.

The BioMalPar conference takes place online and the synchronisation of Plasmodium infection is controlled by the parasite’s own internal clock

Antibody tests for P. vivax malaria could reduce disease prevalence by up to 69% and scientists develop a sex-distorter gene drive that eliminates populations of mosquitoes in the lab.

Scientists find that microsporidia MB stops malaria transmission in Anopheles arabiensis mosquitoes by disrupting oocyst formation.

The combined use of mass drug administration and indoor residual spraying is the most effective way to reduce malaria prevalence in low malaria-endemic settings, and antibodies against PfGARP kill malaria-infected cells by inducing cell death.